News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
44.85 ^USD	+0.34%		-8.34%	-12.59%

09:52pm	S&P 500 Q1 earnings estimated growth improves; stocks up for week	RE
05:50pm	Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

S&P 500 Q1 earnings estimated growth improves; stocks up for week	03:52pm	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	11:50am	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	11:45am	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	10:49am	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	10:48am	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	09:42am	MT
Bristol Myers: positive opinion from the CHMP for Opdivo	08:47am	CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer	08:28am	DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	07:58am	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	07:54am	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	07:24am	MT
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	07:00am	BU
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Sector Update: Health Care	Apr. 25	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	Apr. 25	MT
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall	Apr. 25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST